Trekrezan, an inexpensive synthetic oral drug sold over the counter in Russia in short courses to raise resistance to stress and support immunity, has light evidence: a single study in young men reported preserved performance during cold exposure, while immune, liver, and antioxidant findings come from animals and cell cultures, mostly from the developer's network. Safety appears benign but thin; its value for longevity remains unknown rather than disproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| CBC with differential | WBC 4.5–7.5 ×10⁹/L; lymphocytes 1.5–3.0 ×10⁹/L | Immune and blood-cell effects |
| Hemoglobin | Men 14–16 g/dL; women 13–15 g/dL | Anemia-correction claim |
| ALT and AST | ALT <25 U/L (men), <20 U/L (women); AST <25 U/L | Liver processes the compound |
| Creatinine and eGFR | eGFR >90 mL/min/1.73 m² | Kidneys clear both components |
| Fasting glucose and HbA1c | Glucose 75–90 mg/dL; HbA1c <5.4% | Labeled caution in diabetes |
| hs-CRP | <1.0 mg/L | Inflammation baseline for immune stimulation |
Cadence: Baseline before a first course; typically repeated at the end of the first course (day 8–14), then every 6–12 months for anyone repeating courses several times a year